Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (4,425,914)	$ (4,369,094)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	13,788	9,634
Amortization	318,609	318,609
Stock-based compensation – employees	956,700	514,600
Stock-based compensation – others		77,500
Non-cash interest expense	2,097,986	1,790,975
Non-cash interest expense – related parties	337,312	316,284
Deferred lease expense		40,728
Foreign exchange loss (gain)	38,909	(32,433)
Changes in operating assets and liabilities which provided (used) cash
Lease right-of-use assets	20,019
Other receivable	(3,129)	(241,344)
Accounts payable	(2,534)	109,454
Operating lease liabilities	21,751
Accrued expenses	123,856	75,303
Net cash used in operating activities	(546,149)	(1,389,784)
Cash flows from investing activities
Advances to CEN Biotech Ukraine LLC	(160,000)	(100,000)
Leasehold improvements in progress		(5,439)
Net cash used in investing activities	(160,000)	(105,439)
Cash flows from financing activities
Issuance of convertible notes	689,554	1,227,064
Repayment of convertible notes	(6,000)	(21,600)
Issuance of convertible notes – related parties	20,000
Issuance of loans payable		380,000
Repayment of loans payable		(230,000)
Issuance of loans payable – related parties		225,000
Net cash provided by financing activities	703,554	1,580,464
Net (decrease) increase in cash and cash equivalents	(2,595)	85,241
Cash and cash equivalents, beginning of period	3,193	84,978
Cash and cash equivalents, end of period	598	170,219
Supplemental cash flows disclosures
Cash paid for interest	38,913	33,055
Non-cash transactions - investing and financing activities
Patent acquisition liability modification		$ 4,380,000